Randomized, parallel-group, double-blind, controlled study to evaluate the efficacy and safety of carbohydrate-derived fulvic acid in topical treatment of eczema

Figures & data

Table 1 Investigator assessment of severity of disease

	Placebo (n = 18)				CHD-FA (n = 18)
	Base	±SD	Final	±SD	Base	±SD	Final	±SD
Severity	2.278	0.826	1.222*	0.732	1.833	0.514	0.8331	0.707
Erythema	2.056	0.998	1.056**	0.873	1.176	0.728	0.2352	0.437
Vesiculation	0.333	0.686	0.056	0.236	0.353	0.493	0.000	0.000
Fissuring	0.056	0.236	0.056	0.236	0.000	0.000	0.000	0.000
Scaling	0.500	0.707	0.056***	0.236	0.176	0.529	0.059	0.243

* Notes: P = 0.0009;

** P = 0.0059;

*** P = 0.0313;

1 P < 0.0001;

2 P = 0.0002 (all by Wilcoxon Signed Rank test). (0 = absent, 1 = mild, 2 = moderate, 3 = moderately severe, 4 = severe.)

Abbreviations: CHD-FA, carbohydrate-derived fulvic acid; SD, standard deviation.

Table 2 Investigator assessment of global response to treatment

	Scale response (0–6)
	Average	±SD
Placebo (n = 18)	2.94	1.11
CHD-FA (n = 18)	1.77*	1.00

* Notes: P < 0.05 (by Mann-Whitney U test). 0 = completely clear except for possible residual hyperpigmentation, 1 = almost clear, very significant clearance (about 90%), 2 = marked improvement/significant improvement (about 75%), 3 = moderate improvement (about 50%), 4 = slight improvement (about 25%), but significant disease remaining, 5 = no change (moderate to severe disease), 6 = worse.

Abbreviations: CHD-FA, carbohydrate-derived fulvic acid; SD, standard deviation.

Table 3 Visual analog scale results.

	Percentage scale response (0–100 mm)
	Base	±SD	Final	±SD
Placebo (n = 18)	62.81	20.89	34.72*	26.81
CHD-FA (n = 17)	69.50	14.65	29.60**	19.71

* Notes: P = 0.003;

** P = 0.0005 (both Wilcoxon Signed Rank test).

Abbreviations: CHD-FA, carbohydrate-derived fulvic acid; SD, standard deviation.

Figure 1 Photograph of patient before and after treatment.